Sun Pharma looks to rise in US with $10 billion Organon buy

The transaction, likely to come with a $10 billion price tag inclusive of debt, will arguably be the most audacious takeover bid by Sun’s billionaire founder Dilip Shanghvi, 70, known for his astute deal making. A successful transaction will also make it the largest cross-border acquisition in the Indian pharmaceutical space and give Sun significant heft in the US. One of the persons cited said a deal would be “transformative” for Sun.Sun’s advisors include a European bank, which is putting together a comp ...